U.S. Approval, Sales Milestones Could Double PneumRx Price For BTG
This article was originally published in The Pink Sheet Daily
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the U.K. company’s interventional medicines business.
You may also be interested in...
Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.
Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.